↓ Skip to main content

Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases

Overview of attention for article published in BMC Medicine, January 2013
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (91st percentile)
  • Above-average Attention Score compared to outputs of the same age and source (60th percentile)

Mentioned by

twitter
20 tweeters

Citations

dimensions_citation
32 Dimensions

Readers on

mendeley
98 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Clinical development of monoclonal antibody-based drugs in HIV and HCV diseases
Published in
BMC Medicine, January 2013
DOI 10.1186/1741-7015-11-4
Pubmed ID
Authors

Michela Flego, Alessandro Ascione, Maurizio Cianfriglia, Stefano Vella

Abstract

Today there are many licensed antiviral drugs, but the emergence of drug resistant strains sometimes invalidates the effects of the current therapies used in the treatment of infectious diseases. Compared to conventional antiviral drugs, monoclonal antibodies (mAbs) used as pharmacological molecules have particular physical characteristics and modes of action, and, therefore, they should be considered as a distinct therapeutic class. Despite being historically validated, antibodies may represent a novel tool for combatting infectious diseases. The current high cost of mAbs' production, storage and administration (by injection only) and the consequent obstacles to development are outweighed by mAbs' clinical advantages. These are related to a low toxicity combined with high specificity and versatility, which allows a specific antibody to mediate various biological effects, ranging from the virus neutralization mechanisms to the modulation of immune responses.This review briefly summarizes the recent technological advances in the field of immunoglobulin research, and the current status of mAb-based drugs in clinical trials for HIV and HCV diseases. For each clinical trial the available data are reported and the emerging conceptual problems of the employed mAbs are highlighted.This overview helps to give a clear picture of the efficacy and challenges of the mAbs in the field of these two infectious diseases which have such a global impact.

Twitter Demographics

The data shown below were collected from the profiles of 20 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 98 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 1%
United States 1 1%
Netherlands 1 1%
Unknown 95 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 18 18%
Student > Master 16 16%
Student > Bachelor 12 12%
Researcher 12 12%
Other 8 8%
Other 21 21%
Unknown 11 11%
Readers by discipline Count As %
Agricultural and Biological Sciences 32 33%
Medicine and Dentistry 11 11%
Biochemistry, Genetics and Molecular Biology 11 11%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Social Sciences 4 4%
Other 20 20%
Unknown 12 12%

Attention Score in Context

This research output has an Altmetric Attention Score of 15. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 September 2014.
All research outputs
#1,397,674
of 15,927,636 outputs
Outputs from BMC Medicine
#1,044
of 2,485 outputs
Outputs of similar age
#21,506
of 262,106 outputs
Outputs of similar age from BMC Medicine
#68
of 172 outputs
Altmetric has tracked 15,927,636 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 91st percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 2,485 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.3. This one has gotten more attention than average, scoring higher than 57% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 262,106 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 91% of its contemporaries.
We're also able to compare this research output to 172 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 60% of its contemporaries.